172 related articles for article (PubMed ID: 25756670)
21. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors.
Wang RB; Kuo CL; Lien LL; Lien EJ
J Clin Pharm Ther; 2003 Jun; 28(3):203-28. PubMed ID: 12795780
[TBL] [Abstract][Full Text] [Related]
22. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein.
Dey S; Ramachandra M; Pastan I; Gottesman MM; Ambudkar SV
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10594-9. PubMed ID: 9380680
[TBL] [Abstract][Full Text] [Related]
23. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA; Bagrij T; Neo SY
Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
[TBL] [Abstract][Full Text] [Related]
24. Establishment and Use of Human Mouth Epidermal Carcinoma (KB) Cells Overexpressing P-Glycoprotein To Characterize Structure Requirements for Flavonoids Transported by the Efflux Transporter.
Fang Y; Xia M; Liang F; Cao W; Pan S; Xu X
J Agric Food Chem; 2019 Feb; 67(8):2350-2360. PubMed ID: 30688455
[TBL] [Abstract][Full Text] [Related]
25. Flavonoids as P-gp Inhibitors: A Systematic Review of SARs.
Cui J; Liu X; Chow LMC
Curr Med Chem; 2019; 26(25):4799-4831. PubMed ID: 30277144
[TBL] [Abstract][Full Text] [Related]
26. Role of P-glycoprotein in drug disposition.
Tanigawara Y
Ther Drug Monit; 2000 Feb; 22(1):137-40. PubMed ID: 10688277
[TBL] [Abstract][Full Text] [Related]
27. P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity.
Mechetner EB; Schott B; Morse BS; Stein WD; Druley T; Davis KA; Tsuruo T; Roninson IB
Proc Natl Acad Sci U S A; 1997 Nov; 94(24):12908-13. PubMed ID: 9371774
[TBL] [Abstract][Full Text] [Related]
28. Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators.
Krishna R; Mayer LD
Curr Med Chem Anticancer Agents; 2001 Aug; 1(2):163-74. PubMed ID: 12678765
[TBL] [Abstract][Full Text] [Related]
29. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells.
Anuchapreeda S; Leechanachai P; Smith MM; Ambudkar SV; Limtrakul PN
Biochem Pharmacol; 2002 Aug; 64(4):573-82. PubMed ID: 12167476
[TBL] [Abstract][Full Text] [Related]
30. QSAR modeling of the interaction of flavonoids with GABA(A) receptor.
Duchowicz PR; Vitale MG; Castro EA; Autino JC; Romanelli GP; Bennardi DO
Eur J Med Chem; 2008 Aug; 43(8):1593-602. PubMed ID: 18158201
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and discovery of ocotillol-type amide derivatives as orally available modulators of P-glycoprotein-mediated multidrug resistance.
Ren Q; Yang G; Guo M; Guo J; Li Y; Lu J; Yang Q; Tang H; Li Y; Fang X; Sun Y; Qi JG; Tian J; Wang H
Eur J Med Chem; 2019 Jan; 161():118-130. PubMed ID: 30347326
[TBL] [Abstract][Full Text] [Related]
32. Reversal of Multidrug Resistance in Mouse Lymphoma Cells by Extracts and Flavonoids from Pistacia integerrima.
Rauf A; Uddin G; Raza M; Ahmad B; Jehan N; Siddiqui BS; Molnar J; Csonka A; Szabo D
Asian Pac J Cancer Prev; 2016; 17(1):51-5. PubMed ID: 26838254
[TBL] [Abstract][Full Text] [Related]
33. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
[TBL] [Abstract][Full Text] [Related]
34. Kinetic modelling of the P-glycoprotein mediated efflux with a large-scale matched molecular pair analysis.
Zhao H
Eur J Med Chem; 2023 Dec; 261():115830. PubMed ID: 37774507
[TBL] [Abstract][Full Text] [Related]
35. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes.
Twentyman PR; Rhodes T; Rayner S
Eur J Cancer; 1994; 30A(9):1360-9. PubMed ID: 7999426
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.
Marbeuf-Gueye C; Salerno M; Quidu P; Garnier-Suillerot A
Eur J Pharmacol; 2000 Mar; 391(3):207-16. PubMed ID: 10729360
[TBL] [Abstract][Full Text] [Related]
37. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin.
Chen WS; Luker KE; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D
Biochem Pharmacol; 2000 Aug; 60(3):413-26. PubMed ID: 10856437
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication.
Munagala S; Sirasani G; Kokkonda P; Phadke M; Krynetskaia N; Lu P; Sharom FJ; Chaudhury S; Abdulhameed MD; Tawa G; Wallqvist A; Martinez R; Childers W; Abou-Gharbia M; Krynetskiy E; Andrade RB
Bioorg Med Chem; 2014 Feb; 22(3):1148-55. PubMed ID: 24405813
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance.
Boumendjel A; Di Pietro A; Dumontet C; Barron D
Med Res Rev; 2002 Sep; 22(5):512-29. PubMed ID: 12210557
[TBL] [Abstract][Full Text] [Related]
40. Reconstitution and functional studies of hamster P-glycoprotein in giant liposomes.
Park S; Majd S
PLoS One; 2018; 13(6):e0199279. PubMed ID: 29912971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
